Tesaro
News/ News/ Oncology/ R&D/ Roche/ Top pharmaceutical companies
Tesaro stock rockets as rumours of Roche takeover abound
Joy Persaud
cancer, Clovis Oncology, Oncology, Roche, Rubraca, Tesaro, Zejula
0 Comment
ASCO 2018/ Event coverage/ Oncology/ Views & Analysis/ Views and analysis
ASCO 2018 – Tuesday 5th June: Tesaro developing checkpoint combo
Richard Staines
ASCO 2018, breast cancer, cancer, Loxo, ovarian cancer, Tesaro
0 Comment
Clovis’ PARP drug gets new US ovarian cancer use
Richard Staines
AstraZeneca, cancer, Clovis Oncology, ovarian cancer, Tesaro
0 Comment
Rucaparib gets FDA OK in maintenance use
Clovis’ Rubraca close to EU approval in ovarian cancer
Richard Staines
AstraZeneca, cancer, Clovis Oncology, ovarian cancer, Tesaro
0 Comment
CHMP backs conditional approval for PARP drug
Market Access/ News/ News/ News/ News/ News/ Oncology/ R&D/ Sales and Marketing
Tesaro and Roche to combine drugs in bladder cancer trials
Andrew McConaghie
AstraZeneca, Lynparza, PARP inhibitors, Tesaro
0 Comment
Tesaro is to combine its PARP-inhibitor drug Zejula with Roche’s PD-L1 immunotherapy Tecentriq in clinical trials for metastatic bladder cancer.
Cancer/ News/ News/ News/ Oncology/ R&D/ US
AZ’s Lynparza becomes first PARP drug approved in breast cancer
Richard Staines
AstraZeneca, breast cancer, cancer, Clovis, ovarian cancer, Tesaro
0 Comment
Lynparza first in class approved in breast cancer
Clovis PARP drug gets fast US review in new ovarian cancer use
Richard Staines
AstraZeneca, cancer, Clovis, Merck & Co, ovarian cancer, Tesaro
0 Comment
Impressed by survival data, FDA hastens review in expanded patient group
News/ News/ Oncology/ UK & Europe
Tesaro gets European approval on Zejula, set to challenge AZ
Richard Staines
AstraZeneca, cancer, ovarian cancer, Tesaro
0 Comment
Tesaro’s PARP drug approved in wider ovarian cancer population